Repligen Corporation (RGEN)
RGEN Stock Price Chart
Explore Repligen Corporation interactive price chart. Choose custom timeframes to analyze RGEN price movements and trends.
RGEN Company Profile
Discover essential business fundamentals and corporate details for Repligen Corporation (RGEN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Instruments & Supplies
IPO Date
29 Apr 1986
Employees
1.78K
Website
https://www.repligen.comCEO
Olivier Loeillot
Description
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
RGEN Financial Timeline
Browse a chronological timeline of Repligen Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 27 Apr 2026
Upcoming earnings on 18 Feb 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is $0.42.
Earnings released on 29 Jul 2025
EPS came in at $0.37 falling short of the estimated $0.40 by -7.50%, while revenue for the quarter reached $182.37M , beating expectations by +0.16%.
Earnings released on 29 Apr 2025
EPS came in at $0.39 surpassing the estimated $0.35 by +11.43%, while revenue for the quarter reached $169.17M , missing expectations by -2.53%.
Earnings released on 20 Feb 2025
EPS came in at $0.44 surpassing the estimated $0.41 by +7.32%, while revenue for the quarter reached $167.55M , beating expectations by +2.11%.
Earnings released on 12 Nov 2024
EPS came in at $0.43 surpassing the estimated $0.34 by +28.21%, while revenue for the quarter reached $154.87M , beating expectations by +1.21%.
Earnings released on 30 Jul 2024
EPS came in at $0.33 matching the estimated $0.33, while revenue for the quarter reached $154.07M , missing expectations by -0.03%.
Earnings released on 1 May 2024
EPS came in at $0.28 falling short of the estimated $0.29 by -3.45%, while revenue for the quarter reached $151.35M , beating expectations by +0.86%.
Earnings released on 21 Feb 2024
EPS came in at $0.33 falling short of the estimated $0.34 by -2.94%, while revenue for the quarter reached $155.74M , beating expectations by +0.23%.
Earnings released on 31 Oct 2023
EPS came in at $0.23 surpassing the estimated $0.14 by +64.29%, while revenue for the quarter reached $141.19M , beating expectations by +0.39%.
Earnings released on 2 Aug 2023
EPS came in at $0.53 surpassing the estimated $0.49 by +8.16%, while revenue for the quarter reached $159.17M , missing expectations by -4.07%.
Earnings released on 2 May 2023
EPS came in at $0.64 surpassing the estimated $0.59 by +8.47%, while revenue for the quarter reached $182.66M , beating expectations by +0.68%.
Earnings released on 22 Feb 2023
EPS came in at $0.68 surpassing the estimated $0.58 by +17.24%, while revenue for the quarter reached $186.76M , beating expectations by +1.20%.
Earnings released on 1 Nov 2022
EPS came in at $0.77 surpassing the estimated $0.68 by +13.24%, while revenue for the quarter reached $200.74M , beating expectations by +4.83%.
Earnings released on 2 Aug 2022
EPS came in at $0.91 surpassing the estimated $0.72 by +26.39%, while revenue for the quarter reached $207.63M , beating expectations by +9.82%.
Earnings released on 27 Apr 2022
EPS came in at $0.92 surpassing the estimated $0.72 by +27.78%, while revenue for the quarter reached $206.40M , beating expectations by +11.28%.
Earnings released on 17 Feb 2022
EPS came in at $0.81 surpassing the estimated $0.65 by +24.62%, while revenue for the quarter reached $186.52M , beating expectations by +4.05%.
Earnings released on 28 Oct 2021
EPS came in at $0.78 surpassing the estimated $0.64 by +21.88%, while revenue for the quarter reached $178.22M , beating expectations by +8.69%.
Earnings released on 27 Jul 2021
EPS came in at $0.79 surpassing the estimated $0.52 by +51.92%, while revenue for the quarter reached $162.96M , missing expectations by -0.62%.
Earnings released on 4 May 2021
EPS came in at $0.68 surpassing the estimated $0.42 by +61.90%, while revenue for the quarter reached $142.84M , beating expectations by +21.18%.
Earnings released on 24 Feb 2021
EPS came in at $0.52 surpassing the estimated $0.31 by +67.74%, while revenue for the quarter reached $108.65M , beating expectations by +25.25%.
Earnings released on 5 Nov 2020
EPS came in at $0.40 surpassing the estimated $0.28 by +42.86%, while revenue for the quarter reached $94.06M , beating expectations by +42.86%.
RGEN Stock Performance
Access detailed RGEN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.